Literature DB >> 15920051

Dose-response relationship of oral insulin spray in healthy subjects.

Simona Cernea1, Miriam Kidron, Jay Wohlgelernter, Pankaj Modi, Itamar Raz.   

Abstract

OBJECTIVE: To evaluate the pharmacodynamic and pharmacokinetic properties and the dose-ranging effects of an oral insulin spray in comparison with subcutaneous regular insulin. RESEARCH DESIGN AND METHODS: In this randomized, five-way, cross-over study, seven healthy volunteers were assessed under euglycemic clamp and received four different doses of oral spray and one dose of subcutaneous regular insulin.
RESULTS: The time to maximum insulin concentration was shorter for oral insulin than for subcutaneous insulin (25.9 +/- 9 vs. 145.7 +/- 49.5 min, P < 0.05). Maximum serum insulin levels (C(max)) were comparable between the subcutaneous and 20 puffs of oral insulin (39.1 +/- 19.6 vs. 34.0 +/- 7.4 microU/ml, NS). The Ins-AUC(0-120) (area under the curve from 0 to 120 min for serum insulin) (339.8 +/- 218, 681.3 +/- 407, and 1,586.7 +/- 8 microU/ml, P < 0.05) and C(max) (7.6 +/- 2.8, 16.4 +/- 9.3, and 39.1 +/- 19.6 microU/ml, P < 0.005) proved a dose-response relationship for the three doses of oral insulin (5, 10, and 20 puffs, respectively). Oral insulin had an earlier onset of action (31.7 +/- 12 vs. 77.8 +/- 3 min, P < 0.05), earlier peak (44.2 +/- 10 vs. 159.2 +/- 68 min, P < 0.05), and a shorter duration of action (85.1 +/- 25 vs. 319.2 +/- 45 min, P < 0.05) compared with subcutaneous insulin. The maximum metabolic effect (1.7 +/- 1.0, 3.09 +/- 1.7, and 4.6 +/- 1.5 mg . kg(-1) . min(-1), P < 0.05) and the GIR-AUC(0-120) (amount of glucose infused from 0 to 120 min) (106.7 +/- 74.3, 162.9 +/- 116.1, and 254 +/- 123 mg/kg) increased in a dose-dependent relationship for the three doses.
CONCLUSIONS: Oral insulin was absorbed in direct relation to the amount given and had a faster onset and a shorter duration of action compared with subcutaneous regular insulin. A dose-response relationship in the absorption and metabolic effect of the oral insulin was noted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920051     DOI: 10.2337/diacare.28.6.1353

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  5 in total

Review 1.  Oral insulin and buccal insulin: a critical reappraisal.

Authors:  Lutz Heinemann; Yves Jacques
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

Review 2.  Efficacy and safety of oral insulin compared to subcutaneous insulin: a systematic review and meta-analysis.

Authors:  V Akbari; F Hendijani; A Feizi; J Varshosaz; Z Fakhari; S Morshedi; S A Mostafavi
Journal:  J Endocrinol Invest       Date:  2015-06-24       Impact factor: 4.256

Review 3.  Ultrafast-acting insulins: state of the art.

Authors:  Lutz Heinemann; Douglas B Muchmore
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

4.  Improvement in glycemic control by gastric electrical stimulation (TANTALUS) in overweight subjects with type 2 diabetes.

Authors:  A Bohdjalian; B Ludvik; B Guerci; L Bresler; E Renard; D Nocca; E Karnieli; A Assalia; R Prager; G Prager
Journal:  Surg Endosc       Date:  2008-12-06       Impact factor: 4.584

Review 5.  Role of insulin in the type 2 diabetes therapy: past, present and future.

Authors:  Carlo Maria Rotella; Laura Pala; Edoardo Mannucci
Journal:  Int J Endocrinol Metab       Date:  2013-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.